Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
Parasitology ; 144(4): 384-393, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27876112

RESUMO

Entamoeba histolytica is the causative agent of amoebic liver abscess (ALA), which course with an uncontrolled inflammation and nitro-oxidative stresses, although it is well known that amoeba has an effective defence mechanisms against this toxic environment, the underlying molecular factors responsible for progression of tissue damage remain largely unknown. The purpose of the present study was to determine during the acute stage of ALA in hamsters, the involvement of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and nuclear factor-kappa B (NF-κB), which are activated in response to oxidative stress. From 12 h post-infection the ALA was visible, haematoxylin-eosin and Masson's trichrome stains were consistent with these observations, and alanine aminotransferase, alkaline phosphatase and γ-glutamyl transpeptidase serum activities were increased too. At 48 h after infection, liver glycogen content was significantly reduced. Western blot analyses showed that 4-Hydroxy-2-nonenal peaked at 12 h, while glycogen synthase kinase-3ß, cleaved caspase-3, pNF-κB, interleukin-1ß and tumour necrosis factor-α were overexpressed from 12 to 48 h post-infection. Otherwise, Nrf2 and superoxide dismutase-1, decreased at 48 h and catalase declined at 36 and 48 h. Furthermore, heme oxygenase-1 was increased at 12 and 24 h and decreased to normal levels at 36 and 48 h. These findings suggest for the first time that the host antioxidant system of Nrf2 is influenced during ALA.


Assuntos
Antioxidantes/metabolismo , Entamebíase/parasitologia , Hepatopatias Parasitárias/imunologia , Fator 2 Relacionado a NF-E2/metabolismo , NF-kappa B/metabolismo , Animais , Cricetinae , Entamoeba histolytica , Entamebíase/imunologia , Entamebíase/metabolismo , Regulação da Expressão Gênica/fisiologia , Masculino , Mesocricetus , Fator 2 Relacionado a NF-E2/genética , NF-kappa B/genética
2.
Anticancer Drugs ; 24(4): 394-405, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23388162

RESUMO

We present a study of the chemoprotective effects of two caffeic acid phenethyl ester (CAPE)-related structures: LQM717 and LQM706. The modified resistant hepatocyte model in rats was used to study the chemoprevention of these CAPE analogues, which are inexpensive and easily obtained. In the liver cancer model used, we detected extensive necrosis and lipid peroxidation after 24 h, many altered hepatic foci, putatively preneoplastic lesions with γ-glutamyl transpeptidase staining after 30 days, and liver tumors at 12 months. We tested the effect of the CAPE analogues on necrosis, lipid peroxidation, proliferation, p65 activation, altered hepatic foci, and tumors. Both compounds exerted protective effects on lipid peroxidation, necrosis, cell proliferation, p65 activation, and preneoplastic lesions. Rats under a carcinogenic protocol showed a 52, 71.74, and 51.6% decrease in the number of preneoplastic nodules when pretreated with CAPE, LQM706, and LQM717, respectively. At 12 months after carcinogenic treatment, eight of eight rats developed liver cancer, whereas in the group of rats that received pretreatment with CAPE, LQM706, or LQM717, 62.5, 83.3, or 42.85%, respectively, had tumors. In conclusion, LQM717 has the potential to enhance chemoprotection activity much better than CAPE by markedly reducing the formation of liver cancers in this model, and this is a compound that is easy to obtain.


Assuntos
Acetanilidas/farmacologia , Anticarcinógenos/uso terapêutico , Antioxidantes/uso terapêutico , Ácidos Cafeicos/uso terapêutico , Cinamatos/uso terapêutico , Hepatócitos/efeitos dos fármacos , Neoplasias Hepáticas Experimentais/tratamento farmacológico , Álcool Feniletílico/análogos & derivados , Lesões Pré-Cancerosas/tratamento farmacológico , 2-Acetilaminofluoreno , Acetanilidas/síntese química , Acetanilidas/uso terapêutico , Animais , Anticarcinógenos/síntese química , Anticarcinógenos/farmacologia , Antioxidantes/síntese química , Antioxidantes/farmacologia , Ácidos Cafeicos/farmacologia , Carcinógenos , Divisão Celular/efeitos dos fármacos , Cinamatos/síntese química , Cinamatos/farmacologia , Dietilnitrosamina , Avaliação Pré-Clínica de Medicamentos , Resistência a Medicamentos , Glutationa S-Transferase pi/análise , Hepatectomia/efeitos adversos , Hepatócitos/química , Hepatócitos/patologia , Antígeno Ki-67/análise , Peroxidação de Lipídeos/efeitos dos fármacos , Neoplasias Hepáticas Experimentais/induzido quimicamente , Neoplasias Hepáticas Experimentais/patologia , Masculino , Estrutura Molecular , Álcool Feniletílico/farmacologia , Álcool Feniletílico/uso terapêutico , Lesões Pré-Cancerosas/induzido quimicamente , Lesões Pré-Cancerosas/patologia , Ratos , Ratos Endogâmicos F344 , Fator de Transcrição RelA/antagonistas & inibidores , Fator de Transcrição RelA/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA